# Safety and Effectiveness of TactiCath™ Contact Force, Sensor Enabled™ (TactiCath SE) Catheter for Ablation of Drug Refractory, Symptomatic, Persistent Atrial Fibrillation

Study · id `cardio:ct-nct03650556` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03650556](<https://clinicaltrials.gov/study/NCT03650556>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03650556

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 224 participants.

## Technical summary

Registry record NCT03650556. Allocation not applicable; no masking; primary purpose treatment. Start 2018-09-28 (actual); primary completion 2020-12-21 (actual). Results posted on 2022-04-27.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 224 participants (enrolled count; ClinicalTrials.gov record NCT03650556, source copy `cardio:ctgov-nct03650556-2022-04-27`, retrieved 2026-10-26)
- Started: 2018-09-28 (actual) (ClinicalTrials.gov record NCT03650556, source copy `cardio:ctgov-nct03650556-2022-04-27`, retrieved 2026-10-26)
- Primary completion: 2020-12-21 (actual) (ClinicalTrials.gov record NCT03650556, source copy `cardio:ctgov-nct03650556-2022-04-27`, retrieved 2026-10-26)
- Completion: 2021-01-11 (actual) (ClinicalTrials.gov record NCT03650556, source copy `cardio:ctgov-nct03650556-2022-04-27`, retrieved 2026-10-26)
- Results first posted: 2022-04-27 (ClinicalTrials.gov record NCT03650556, source copy `cardio:ctgov-nct03650556-2022-04-27`, retrieved 2026-10-26)
- Countries: United States; Australia (ClinicalTrials.gov record NCT03650556, source copy `cardio:ctgov-nct03650556-2022-04-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03650556-2022-04-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Effectiveness of TactiCath™ Contact Force, Sensor Enabled™ (TactiCath SE) Catheter for Ablation of Drug Refractory, Symptomatic, Persistent Atrial Fibrillation
- Condition: Persistent Atrial Fibrillation
- Intervention (Device): TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™
- Lead sponsor: Abbott Medical Devices
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Abbott (`cardio:abbott`)

## Provenance

Content hash: 88378101d1919d493db8bc1ef6debf2cc00d8de9165052ec51e2e85ccd20008d
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
